Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

4503 - CARCINOMA OF UNKNOWN ORIGIN: Deep Genomic profile helps to achieve an accurate diagnosis.

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Amaya Fernandez Díaz

Citation

Annals of Oncology (2018) 29 (suppl_8): viii649-viii669. 10.1093/annonc/mdy303

Authors

A.B. Fernandez Díaz1, V. Iranzo Gonzalez-Cruz2, A.J. Cunquero Tomas3, C. Avila Andrade1, E. Jantus-Lewintre4, S. Calabuig Fariñas5, J.E. Ales6, M. Valero7, G. D'Errico8, R.A. Pazo Cid9, A. Gallego Martínez10, A. Viana11, S. Ponce Aix12, J.A. Pérez-Fidalgo13, A. Terradez14, A. Rodrigo14, L. Alvarez14, G. Beniuga15, M. Martorell16, C. Camps17

Author affiliations

  • 1 Medical Oncology Service, Dep. of Medical Oncology, Hospital General Universitario de Valencia, Valencia, Spain, 46018 - Valencia/ES
  • 2 Medical Oncology Service, Dep. of Medical Oncology, Hospital General Universitario de Valencia, Valencia, Spain; Centro Investigación Biomédica en Red de Cáncer (CIBEROnc), 46018 - Valencia/ES
  • 3 Medical Oncology, Hospital General Universitario Valencia, 46018 - Valencia/ES
  • 4 Laboratorio De Oncología Molecular, Fundación Para La Investigación, Hospital General Universitario De Valencia-ciberonc, Valencia, Spain, Molecular Oncology Lab. Fundación Investigación Hospital General Universitario Valencia, Valencia, Spain; Centro Investigación Biomédica en Red de Cáncer (CIBEROnc), Madrid, Spain; Dep. of Biotechnology, Universitat Politècnica València, Valencia, Spain, 46014 - Valencia/ES
  • 5 Medical Oncology Service, Molecular Oncology Lab. Fundación Investigación Hospital General Universitario Valencia, Valencia, Spain; Centro Investigación Biomédica en Red de Cáncer (CIBEROnc), Madrid, Spain; Dep. of Pathology, Universitat de València, Valencia, Spain, 46018 - Valencia/ES
  • 6 Medical Oncology, Hospital Nuestra Señora de Sonsoles, 5004 - AVILA/ES
  • 7 Medical Oncology, ONCOAVANZE, 41013 - SEVILLA/ES
  • 8 Medical Oncology, Hospital Universitario Quirónsalud Madrid, 28223 - MADRID/ES
  • 9 Medical Oncology, Hospital Miguel Servet, 50009 - Zaragoza/ES
  • 10 Medical Oncology, Hospital Universitario La Paz, 28046 - Madrid/ES
  • 11 Medical Oncology, Hospital Nuestra Señora del Prado, 45600 - TOLEDO/ES
  • 12 Medical Oncology, University Hospital 12 De Octubre, 28041 - Madrid/ES
  • 13 Medical Oncology, Hospital Clínico Universitario de Valencia, 46010 - Valencia/ES
  • 14 Scientific Department, OncoDNA S.A., 6041 - Gosselies/BE
  • 15 Pathology Department., Institute Pathology and Génétique, 6041 - Charleroi/BE
  • 16 Pathology Department., Dep. of Pathology, Hospital General Universitario de Valencia, Valencia, Spain; Dep. of Pathology, Universitat de València, Valencia, Spain, 46014 - VALENCIA/ES
  • 17 Medical Oncology, Dep. of Medical Oncology, Hospital General Universitario de Valencia, Valencia, Spain; Centro Investigación Biomédica en Red de Cáncer (CIBEROnc), Madrid, Spain; Dep. of Medicine, Universitat de València, Valencia, Spain, 46014 - Valencia/ES
More

Resources

Abstract 4503

Background

Diagnosis and treatment of Cancer of Unknown Origin (CUP) continues to be a challenge. In the era of personalized medicine, genomic profile by Next-Generation-Sequencing (NGS) in addition to immunohistochemistry (IHC) tests may complement clinical features improving diagnosis and detecting targetable mutations. In the present study we have analysed the clinical utility of theOncoDEEP® CUP platformfor tissue of origin assessment and genotyping in a cohort of CUP patients.

Methods

We conducted this multicentric prospective exploratory study across 22 institutions (September 2017- March 2018). The cohort included 60 patients with histologically diagnosed metastatic CUP and available FFPE tumor samples. The molecular analysis was performed using the OncoDEEP® CUP platform, which includes a deep genomic tumor characterization as well as a panel of IHC tests.

Results

Patient’s median age was 60 years [24-80], 61.7% were females. At time of diagnosis,48% presented a single metastatic site whereas 52% has multimetastaticlocations. Predominant histology was adenocarcinoma (36.7%) followed by carcinoma NOS (25%), squamous cell carcinoma (13.3%) and others (25%). In 10% of the cases, the analysis could not be completed due to insufficient tumor samples. In the remaining 54 samples, a probable primary origin was assessed in 43 patients (80%). Potentially actionable mutations were found in 36 cases (61%). As expected, the most frequently mutated gene was TP53 (12/36), followed by KRAS, TPMT, ARID1A,BRAF, CDKN2A, PI3KCA, PTEN and STK11. During follow up 11 deaths have been recorded, whereas the rest of the patients remain in the study.

Conclusions

OncoDEEP® CUP may provide an opportunity for CUP patients to benefit from site-specific treatments and personalized therapies if druggable mutations are identified. Acknowledgments to the rest collaborating centers: H. U. de Ceuta, H. U. Virgen Macarena, H. Ramón y Cajal, H. U. Santa Lucía, HC Marbella International Hospital, H. Parc Taulí, H. U. La Ribera, H. Marina Baixa, H. Morales Meseger, H. U. Lucus Augusti and Instituto Valenciano de Oncología (IVO).

Clinical trial identification

Legal entity responsible for the study

Hospital General Universitario de Valencia, Valencia, Spain, Valencia.

Funding

The Spanish Institute for Foreign Trade (ICEX).

Editorial Acknowledgement

Disclosure

A. Terradez, A. Rodrigo, L. Alvarez, G. Beniuga: Employee: OncoDNA. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings